P. L. Carl

发表

Protease-activated "prodrugs" for c (plasminogen activator/plasmin/fibrinolysis/antineoplastic agent!

Michael J. Weber, P. Chakravarty, P. L. Carl, 2016 .

Proteins in assemblages formed by phase separation possess properties that promote their transformation to autoantigens: Implications for autoimmunity.

H. Fried, P. Cohen, P. L. Carl, 2020, Journal of autoimmunity.

A novel connector linkage applicable in prodrug design.

J. Katzenellenbogen, P. Chakravarty, J A Katzenellenbogen, 1981, Journal of medicinal chemistry.

On the molecular weight and subunit composition of calf thymus ribonuclease H1.

P. L. Carl, Y. Rong, Yi Wei Rong, 1990, Biochemistry.

Plasminogen activator in normal and tumor‐bearing mice

P. L. Carl, M. J. Weber, Margaret R. Bruesch, 1983, International journal of cancer.

Protease-activated "prodrugs" for cancer chemotherapy.

J. Katzenellenbogen, M. Weber, P. Chakravarty, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.

J. Katzenellenbogen, M. Weber, P. Chakravarty, 1983, Journal of medicinal chemistry.

Specificity of the Antiviral Agent Calcium Elenolate

J. Heinze, P. L. Carl, A. H. Hale, 1975, Antimicrobial Agents and Chemotherapy.

Reinitiation of deoxyribonucleic acid synthesis by deoxyribonucleic acid initiation mutants of Escherichia coli: role of ribonucleic acid synthesis, protein synthesis, and cell division

P. L. Carl, M. H. Hanna, 1975, Journal of bacteriology.

The effects of organic solvents on Escherichia coli DNA polymerase III.

J. Heinze, P. L. Carl, 1975, Biochimica et biophysica acta.

Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.

J. Katzenellenbogen, M. Weber, P. Chakravarty, 1983, Journal of medicinal chemistry.

Isolation and mapping of a mutation in Escherichia coli with altered levels of ribonuclease H

R. Crouch, P. L. Carl, L. Bloom, 1980, Journal of bacteriology.

Escherichia coli mutants with temperature-sensitive synthesis of DNA

P. L. Carl, 2004, Molecular and General Genetics MGG.

Role of angiotensin II and vasopressin in cisplatin-induced emesis.

L. Cubeddu, W. Wetsel, C. Lindley, 1990, Life sciences.

Do humoral factors mediate cancer chemotherapy-induced emesis?

R. D. Myers, L. Cubeddu, A. Rezvani, 1989, Drug metabolism reviews.

A peptidyl derivative of [3H]aniline as a sensitive, stable, protease substrate.

J. Katzenellenbogen, M. Weber, D. Kohn, 1979, Analytical biochemistry.

Genetic map location of the Escherichia coli dnaG gene

P. L. Carl, P. L. Chen, 1975, Journal of bacteriology.

Triton X-100 activates nucleoside triphosphate-dependent, recBC-dependent DNA synthesis in toluene-treated Escherichia coli.

P. L. Carl, P. L. Chen, D. J. Harper, 1977, Biochimica et biophysica acta.

Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity

P. Cohen, B. Temple, P. L. Carl, 2005, Arthritis research & therapy.

1-beta-D-arabinofuranosylcytosine enhancement of resistance to several antineoplastic drugs in mammalian tissue culture cells.

T. Tlsty, P. L. Carl, B. Goz, 1989, Molecular pharmacology.

PLASMIN-ACTIVATED PRODRUGS FOR CANCER CHEMOTHERAPY. 2. SYNTHESIS AND BIOLOGICAL ACTIVITY OF PEPTIDYL DERIVATIVES OF DOXORUBICIN

J. Katzenellenbogen, P. Chakravarty, P. L. Carl, 1983 .

A mutation in the rnh-locus of Escherichia coli affects the structural gene for RNase H. Examination of the mutant and wild type protein.

A. Sugino, P. L. Carl, J. Arendes, 1982, The Journal of biological chemistry.